RxDoctor Payments Data

Trieu Tran, MD

Orthopaedic Surgery · Fountain Valley, CANPI 1528179660

Payments from drug & device makers

$8,153in general payments, 2019–2025

Across 39 payments — averaging $209.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Stryker$414
  • Biotissue Holdings Inc.$229
  • Amgen$122
  • Micromed Inc$118
  • Merck$43
  • plus $106 from 3 others

What the payments were for

  • Food & beverage$1,11714%
  • Other$7,03686%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(3 entities)6$7,120
Stryker19$414
Biotissue Holdings Inc.5$229
Amgen1$122
Micromed Inc1$118
Merck3$43
Medartis Inc.1$40
AbbVie2$34
Vertex1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,153 in reported general payments places this provider in the 65th percentile of 1,808 orthopaedic surgery providers in California.

See all orthopaedic surgery providers in California

Medicare billing

Part B allowed, 2024
$288,532
Medicare patients
682
Services billed
9,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban20$5,947
Diclofenac Sodium57$4,820
Celecoxib178$2,164
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$820
Acetaminophen-CodeineAcetaminophen With Codeine53$454
Meloxicam172$448
Naproxen77$437
Gabapentin108$404
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$284
Omeprazole30$95
Ibuprofen11$83
Ciprofloxacin Hcl19$81
Prednisone18$68
Triamcinolone Acetonide15$61
Tramadol Hcl13$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$7,120$5,94720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,808 orthopaedic surgery providers in California.

Other orthopaedic surgery in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →